Paisu Shuanglin: Wholly-owned subsidiary Rennin-coagulase granted approval for drug registration clinical trial.

Parse Dual Forest announced that its wholly-owned subsidiary, Guangdong Dual Forest, has received the "Notice of Acceptance" for the registration clinical trial of human thrombin drug approved and issued by the National Medical Products Administration. The drug is a lyophilized powder for external use only, with a specification of 5000IU per bottle. The declared indications are for assisting hemostasis in capillary and small venous oozing and minor bleeding. Currently, Huallan Biotechnology and Shanghai Lai Shi have obtained approval for the marketing of this product. The acceptance of this trial will not affect the current performance, but in the long term, it can enrich the product line and enhance competitiveness. However, there is uncertainty in drug development, and the company will disclose information according to progress.